Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

Vázquez, Marta; Guevara, Natalia; Maldonado, Cecilia; Guido, Paulo Cáceres; Schaiquevich, Paula

doi:10.1155/2020/3902740

Cited by 37 publications

(31 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is recommended here that CUD patients should be carefully monitored when they take other medicines. Drug–drug interaction between cannabinoids and other classes of drugs has been previously reported [ 61 , 62 ].…”

Section: Discussionmentioning

confidence: 99%

Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients

et al. 2021

View full text Add to dashboard Cite

Cannabis use has been growing recently and it is legally consumed in many countries. Cannabis has a variety of phytochemicals including cannabinoids, which might impair the peripheral systems responses affecting inflammatory and immunological pathways. However, the exact signaling pathways that induce these effects need further understanding. The objective of this study is to investigate the serum proteomic profiling in patients diagnosed with cannabis use disorder (CUD) as compared with healthy control subjects. The novelty of our study is to highlight the differentially changes proteins in the serum of CUD patients. Certain proteins can be targeted in the future to attenuate the toxicological effects of cannabis. Blood samples were collected from 20 male individuals: 10 healthy controls and 10 CUD patients. An untargeted proteomic technique employing two-dimensional difference in gel electrophoresis coupled with mass spectrometry was employed in this study to assess the differentially expressed proteins. The proteomic analysis identified a total of 121 proteins that showed significant changes in protein expression between CUD patients (experimental group) and healthy individuals (control group). For instance, the serum expression of inactive tyrosine protein kinase PEAK1 and tumor necrosis factor alpha-induced protein 3 were increased in CUD group. In contrast, the serum expression of transthyretin and serotransferrin were reduced in CUD group. Among these proteins, 55 proteins were significantly upregulated and 66 proteins significantly downregulated in CUD patients as compared with healthy control group. Ingenuity pathway analysis (IPA) found that these differentially expressed proteins are linked to p38MAPK, interleukin 12 complex, nuclear factor-κB, and other signaling pathways. Our work indicates that the differentially expressed serum proteins between CUD and control groups are correlated to liver X receptor/retinoid X receptor (RXR), farnesoid X receptor/RXR activation, and acute phase response signaling.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pharmacokinetic DDIs are those that affect the absorption, distribution, metabolism, and excretion of a concomitantly administered drug ( Rabba et al, 2020 ). This change can lead to the change of the concentration of drug at the action site, thus affecting the duration and magnitude of the effect ( Vázquez et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

Ruan

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: A robust, quick, and reliable ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for the quantification of erdafitinib in beagle dog plasma was developed and validated to evaluate the changes of posaconazole and isavuconazole on the pharmacokinetics of erdafitinib in beagle dogs, respectively.Methods: This experiment adopted a three-period self-control experimental design. In the first period (group A), erdafitinib was orally administered to six beagle dogs at a dose of 4 mg/kg. In the second period (group B), the same six beagle dogs were orally given posaconazole at a dose of 7 mg/kg, and after 30 min, erdafitinib was orally given. In the third period (group C), isavuconazole at a dose of 7 mg/kg was given orally, and then, erdafitinib was orally given. At the different time points after erdafitinib was given in the three periods, the blood samples were collected. The concentration of erdafitinib was detected by the developed UPLC-MS/MS method. DAS 2.0 was used to calculate the pharmacokinetic parameters of erdafitinib.Results: Erdafitinib had a good linear relationship in the range of 1–500 ng/ml, and the lower limit of quantification was 1 ng/ml. The precision, accuracy, extraction recovery, matrix effect, and stability meet the requirements of the guiding principles. After erdafitinib was combined with posaconazole, the Cmax and AUC0→t of erdafitinib increased by 27.19% and 47.62%, respectively, and the t1/2 was prolonged to 6.33 h. After erdafitinib was combined with isavuconazole, the Cmax and AUC0→t of erdafitinib increased by 23.13% and 54.46%, respectively, and the t1/2 was prolonged to 6.31 h.Conclusion: A robust and reliable UPLC-MS/MS method was fully optimized and developed to detect the plasma concentration of erdafitinib in beagle dogs. Posaconazole and isaconazole could inhibit the metabolism of erdafitinib in beagle dogs and increase the plasma exposure of erdafitinib.

show abstract

“…Cannabinoid Cannabinoid Effect Anesthetic CYP2B6 THC, CBD THC and CBD both are inhibitors [300] Propofol [301], Ketamine [302,303] CYP2C9 THC, Cannabinol [304] THC as inhibitor [300,305] Propofol [301], Ketamine [302,303], Rocuronium [306] CYP2E1 THC metabolites, CBD Competetive inhibition [300] Halothane [307], Isoflurane [307], Sevoflurane [307], Enflurane [307], Desflurane [307,308] CYP3A4 THC, CBD, Cannabinol CBD is an inhibitor [300,309] Ketamine [302], Midazolam [310], Diazepam [311], Fentanyl [312], Rocuronium [306], Codeine [307,313], Propofol [301], Acetaminophen [314] CYP2A6 THC Genotype-dependent [295] Dexmedetomidine [315] CYP2C19 THC, CBD THC and CBD are both inhibitors [309] Diazepam [311], Rocuronium [306] CYP1A1/2 CBD CBD is an inducer [309] Diazepam [311] CYP2D6 THC, CBD THC and CBD are both inhibitors [300] Tramadol [316], Codeine [314,317], Oxycodone [314,318], Hydrocodone…”

Section: Cytochromementioning

confidence: 99%

Considerations for Cannabinoids in Perioperative Care by Anesthesiologists

Laudański

Wain

2022

JCM

View full text Add to dashboard Cite

Increased usage of recreational and medically indicated cannabinoid compounds has been an undeniable reality for anesthesiologists in recent years. These compounds’ complicated pharmacology, composition, and biological effects result in challenging issues for anesthesiologists during different phases of perioperative care. Here, we review the existing formulation of cannabinoids and their biological activity to put them into the context of the anesthesia plan execution. Perioperative considerations should include a way to gauge the patient’s intake of cannabinoids, the ability to gain consent properly, and vigilance to the increased risk of pulmonary and airway problems. Intraoperative management in individuals with cannabinoid use is complicated by the effects cannabinoids have on general anesthetics and depth of anesthesia monitoring while simultaneously increasing the potential occurrence of intraoperative hemodynamic instability. Postoperative planning should involve higher vigilance to the risk of postoperative strokes and acute coronary syndromes. However, most of the data are not up to date, rending definite conclusions on the importance of perioperative cannabinoid intake on anesthesia management difficult.

show abstract

Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

Cited by 37 publications

References 114 publications

Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients

Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

Considerations for Cannabinoids in Perioperative Care by Anesthesiologists

Contact Info

Product

Resources

About